Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma

NCT05646082 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.

NCT NCT05646082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05646082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma
Lead sponsor
Imperial College London
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 26, 2023
Completion date
December 31, 2026
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory hiv associated kaposi sarcoma